Our Leadership

AbGenomics’ senior management is built on a team of individuals possessing strong academic knowledge, high-level managerial experience and scientific expertise in a range of fields including life science, pharmacology, healthcare and immunology.

Ron (R.H.) Lin, Ph.D.

Chief Executive Officer

Dr. Lin is the founder of AbGenomics. He is the key inventor of more than a dozen worldwide patents. Prior to joining AbGenomics, Dr. Lin was Professor and Director of Graduate Institute of Immunology, College of Medicine, National Taiwan University. Dr. Lin also served as an Associate Editor for Journal of Biomedical Science and a member of the Editorial Board for Int. Immunopharmacology. He received his Diplom, Summa Cum Laude, and Doctor (in Immunology), Magna Cum Laude, degrees from the University of Tübingen in Germany. He has conducted his research works in 3 world renowned institutions: Max Planck Institute for Immunogenetics in Germany, Basel Institute for Immunology in Switzerland, and Immunobiology Division at Howard Hughes Medical Institute at Yale University. In his previous academic research journey he has conducted translational researches and published more than 50 refereed papers.

Shih-Yao Lin, MD., Ph.D.

Chief Medical Officer and President of AbG BV

Prior to joining AbGenomics, Dr. Lin was a research fellow (1998-2004) at Laboratory of Allergy and Immunology, Department of Experimental Pathology, in Boston, USA. Dr. Lin received his MD degree from School of Medicine, National Taiwan University, and completed the resident training at the Department of Laboratory Medicine, National Taiwan University Hospital. He also received the PhD degree (Immunology) from Centre d'Immunologie de Marseille-Luminy, University of Aix-Marseille II in Marseille, France.

Leewen Lin, Ph.D., LL.M.

Vice President of Administration, AbG BV Taiwan

Dr. Leewen Lin leads the development of the company’s infrastructure and paved the solid foundation for its growth. Prior to AbGenomics, Dr. Lin had been Senior Staff Fellow in Center of Biologics Evaluation and Research, US Food and Drug Administration, Director of Biotechnology Development Program of Yung-Shin Pharmaceutical, and Vice President of BioTrust International Corporation. Dr. Lin was also a member of the Intellectual Property Committee of Academia Sinica, and served as an advisor to the Biotechnology and Pharmaceutical Promotion Group, Ministry of Economic Affairs, Taiwan, on legal and regulatory affairs. Dr. Lin received her Ph.D. in Biochemistry from North Carolina State University, and obtained her postdoctoral training in Genetics and Molecular Biology in Harvard Medical School and Massachusetts General Hospital. In addition, she enrolled in the J.D. program in Georgetown Law School while working full time at FDA. She received her L.L.M at Soochow University Law School, Taipei, Taiwan.

Hazel (T.Y.) Cheng, Ph.D.

Vice President of Project and Alliance Management

With more than 20 years experiences in biotech and pharma industries, Dr. Cheng expertizes in investigational new drug enabling program, and drug development, strategic sourcing, project management and clinical operation. Prior to joining AbGenomics, she was Vice President of Science and Technology at Westar Nutrition Corp., Costa Mesa in California where she led the research development team, oversee the logistics of manufacture operation and ensure the pharmaceutical cGMP and regulatory compliance. Dr. Cheng received her Ph.D. in Immunology from National Taiwan University School of Medicine.

Hsiao-Wen Tuan, MBA

Associate Vice President of Finance

Prior to joining AbGenomics, Mr. Tuan held senior management positions in companies of Asialoc Corporation, Shye Shyang Mechanical Industrial Co., Ltd., and Yuanta Securities. Tuan is an expert in financial planning with considerable experience, including doing financial planning in China. He received his B.B.A. in money and banking from National Chengchi University, M.B.A in finance from Tamkang University.

Patrick Y. Yang, Ph.D.

Chairman of the Board (Independent Director, Member of Audit Committee and Member of Compensation Committee)

Dr. Yang is an independent consultant for the biopharmaceutical industry since 2013. From 2017 to 2019, he served as Executive Vice President at Juno Therapeutics, Inc. Previously from 2010 to 2013, Dr. Yang served as Executive Vice President and Global Head of Technical Operations for F. Hoffmann-La Roche Ltd., where he was responsible for Roche's pharmaceutical and biotech manufacturing operations, process development, quality, regulatory, supply management, distribution, and engineering functions. Before joining Roche, Dr. Yang worked for Genentech, Inc., where he most recently served as Executive Vice President of Product Operations. Prior to joining Genentech, Dr. Yang worked for Merck & Co., where he held several leadership roles including Vice President of Asia/Pacific Manufacturing Operations and Vice President of Global Supply Chain Management. He also previously worked at General Electric Co. and Life Systems, Inc. in various research, development, engineering, and manufacturing roles. Dr. Yang currently serves on the board of directors of Codexis, Inc., a public company that develops biocatalysts for the pharmaceutical and fine chemicals markets, since 2014; PharmaEssentia Corporation, a public biotechnology company, since 2014; and Amyris, Inc., a public synthetic biology company, since 2014. He also serves on the boards of several private companies. Dr. Yang earned a Bachelor of Science in Electronic Engineering from National Chiao Tung University in Taiwan, a Master of Science in Electrical Engineering from the University of Cincinnati and a Ph.D. in Engineering from The Ohio State University.

Yung-Hua Chung

Mr. Chung started leading EuroKing Co., Ltd. as the Chairman and President since 1993. Aside from this Chairman position, he is also the Board Director for Well-Being Biochemical Corp. and Board Director of AbGenomics Corp., Ltd.
His earlier career was in Collins Co. as a Manager.

Oak Grove Investments Group Limited

A company focused on new drug development was established in the British Virgin Islands in December 2012.

Mark Glory International Limited

A company focused on new drug development was established in Samoa in September 2004.

Nai-Yu Pai, CPA

(Independent Director, Chairman of Audit Committee and Compensation Committee)

Mr. Nai-Yu Pai, the founder of Pai Accountancy LLP, is a Certified Public Accountant who holds a Master’s Degree in Accounting from Saint John’s University in New York, where his primary area of emphasis in taxation and auditing. He also holds another Master’s degree in Taxation from Golden Gate University. Mr. Pai has over 35 years of accounting and auditing experience. Mr. Nai-Yu Pai has founded several companies such as: Authenex Inc. He also serves as the company’s CEO and the member of the Board. F2ware Inc. Gaia Interactive Inc. Mr. Pai is co founder and a member of the Board until December, 31, 2016. Mr. Pai serves as board of director for several companies such as: Sigrity Inc. and Vivente, Inc. Mr. Pai was the Board of Director and Chairman of the Audit Committee of JAsolar (listed on NASDAQ) and AbGenomics International Inc. Mr. Pai has assisted over 20 companies in fund raising, Merger and acquisition activities such as; Marvell Semiconductor, @Road, Silicon Motion Inc, ADMtech, Accton, Hot rail, Amlogic, Global Manufacture and others. Mr. Pai serves as the Board of Director/CFO of Chinese Cancer memorial Foundation who hosted a Tsai Chin Concerts every other year in the USA. Each event raised over one million dollars for cancer patients.

Ron (R.H.) Lin, Ph.D.

Chief Executive Officer

Dr. Lin is the founder of AbGenomics. He is the key inventor of more than a dozen worldwide patents. Prior to joining AbGenomics, Dr. Lin was Professor and Director of Graduate Institute of Immunology, College of Medicine, National Taiwan University. Dr. Lin also served as an Associate Editor for Journal of Biomedical Science and a member of the Editorial Board for Int. Immunopharmacology. He received his Diplom, Summa Cum Laude, and Doctor (in Immunology), Magna Cum Laude, degrees from the University of Tübingen in Germany. He has conducted his research works in 3 world renowned institutions: Max Planck Institute for Immunogenetics in Germany, Basel Institute for Immunology in Switzerland, and Immunobiology Division at Howard Hughes Medical Institute at Yale University. In his previous academic research journey he has conducted translational researches and published more than 50 refereed papers.